SA
PBE icon

Strategic Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Strategic Advisors’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,501
Closed -$227K – 205
2024
Q1 		$227K Sell
3,501
-99
-3% -$6.44K 0.04% 187
2023
Q4 		$237K Sell
3,600
-522
-13% -$30.4K 0.04% 183
2023
Q3 		$235K Hold
4,122
– – 0.05% 180
2023
Q2 		$253K Buy
4,122
+15
+0.4% +$936 0.05% 172
2023
Q1 		$258K Buy
+4,107
New +$265K 0.05% 177

Other funds holding PBE

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CW
CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Strategic Advisors's PBE Position: Q2 2024 in Review

Strategic Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2024, closing a stake of 3,501 shares — an estimated $227K sold.

Strategic Advisors first reported a position in PBE in Q1 2023 and held it in 5 quarters. The position peaked at $258K in Q1 2023. 100 funds tracked by Wall St. Rank hold PBE as of Q2 2024.

  • Strategic Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2024 after selling out during the quarter.
  • Strategic Advisors sold 3,501 Invesco Biotechnology & Genome ETF shares in Q2 2024, an estimated $227K.
  • Strategic Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q1 2023 and held it in 5 quarters.
  • Strategic Advisors's Invesco Biotechnology & Genome ETF position peaked at $258K in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2024.

Based on Strategic Advisors's 13F filing for Q2 2024, filed 11 Jul 2024.